---
title: Defining pathogenic IL-17 and CSF-1 gene expression signatures in chronic graft-versus-host
  disease
date: '2025-02-20'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/39977705/?utm_source=curl&utm_medium=rss&utm_campaign=journals&utm_content=7603509&fc=None&ff=20250221170832&v=2.18.0.post9+e462414
source: Blood
description: Chronic graft-versus-host disease (cGVHD) remains the leading cause of
  non-relapse morbidity and mortality after allogeneic hematopoietic cell transplantation
  (HCT). Effective therapeutics agents targeting dysregulated cytokines including
  IL-17 and CSF-1 have been defined in preclinical models of cGVHD, and efficacy in
  subsequent clinical trials has led to their recent FDA approval. Despite this, these
  agents are effective in only a subset of patients, expensive, difficult to access
  outside ...
disable_comments: true
---
Chronic graft-versus-host disease (cGVHD) remains the leading cause of non-relapse morbidity and mortality after allogeneic hematopoietic cell transplantation (HCT). Effective therapeutics agents targeting dysregulated cytokines including IL-17 and CSF-1 have been defined in preclinical models of cGVHD, and efficacy in subsequent clinical trials has led to their recent FDA approval. Despite this, these agents are effective in only a subset of patients, expensive, difficult to access outside ...